Objective:To investigate the efficacy and safety of statins combined with aspirin in the treatment of cardiovascular diseases.Methods:Randomized controlled clinical trials on the combination of statins and aspirin for cardiovascular diseases was retrievaled in PubMed and CNKI from the establishment of the database to December 12,2022.The literature was screened according to the inclusion and exclusion criteria.The risk of bias was evaluated based on Cochrane 5.1.0,literature quality evaluation and Meta-analysis were conducted using Review Manager 5.4 software.Results:Twenty-six relevant papers were included,and the Meta-analysis results showed that the combination of statins and aspirin significantly reduced the patients'cardiovascular disease exacerbation(WMD =0.13,95%CI 0.11-0.14,P＜0.001),cardiovascular disease mortality(WMD =2.98,95%CI 0.18-5.79,P<0.001)and serum total cholesterol(WMD = 0.91,95%CI 0.20-1.62,P = 0.01),lowdensity lipoprotein(LDL)cholesterol(WMD =0.92,95%CI 0.22-1.61,P =0.010),high density lipoprotein(HDL)cholesterol levels(WMD =0.66,95%CI 0.21-1.61,P =0.01).95%CI 0.09-1.22,P =0.02),and reduced the incidence of adverse drug reactions(WMD =10.29,95%CI 7.09-13.48,P<0.001).Conclusion:The combination of statins and aspirin has certain advantages in the treatment of cardiovascular diseases and is worthy of clinical promotion.
维普
万方数据
